GRT-C903/GRT-R904

Phase 1Biologic

NNational Cancer Institute (NCI)

GRT-C903/GRT-R904 is one of 6 biologic programs targeting Metastatic Solid Cancers. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Solid CancersActive, not recruiting

Metastatic Solid CancersPhase 1

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Metastatic Solid Cancers

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 1

1 2

Proleukin

IIovance Biotherapeutics, Inc.

Phase 1

1 3

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 4

PD-L1 T-Hank

IImmunityBio, Inc.

Phase 1

1 5

GRT-C903/GRT-R904

NNational Cancer Institute (NCI)

Phase 1

1 6

KRAS TCR-Transduced PBL

NNational Cancer Institute (NCI)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Active, not recruiting

Metastatic Solid Cancers

NCT06253520

Clinical

Trials by Indication[1]

Metastatic Solid Cancers1 trial

A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06253520·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GRT-C903/GRT-R904. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GRT-C903/GRT-R904 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GRT-C903/GRT-R904. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

GRT-C903/GRT-R904

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Metastatic Solid Cancers1 trial

References

Drug Info

Quick Facts

Related News